A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Trial Profile

A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs BLU 285 (Primary)
  • Indications Gastrointestinal stromal tumours; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 02 Aug 2017 Blueprint Medicines anticipates completing enrollment of the PDGFRa D842V expansion cohort(n= 50 patients) by the middle of 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Jun 2017 Interim results published in a Blueprint Medicines media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top